The Myriad myPath Melanoma molecular diagnostic test was effective in helping practitioners differentiate between benign and malignant melanocytic lesions, according to results from a prospective study.
Kelly Goff, MD
Advertisement
Articles by Kelly Goff, MD
Advertisement
Latest Updated Articles
Novel Molecular Test Contributes to Definitive Diagnosis in MelanomaFebruary 12th 2015
Advertisement
Advertisement
Trending on OncLive
1
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
2
Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC
3
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
4
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
5